Drug Trial Radar · NCT06595004
A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients
Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
310
Actual
Start
Nov 22, 2024
Primary completion
Jun 18, 2025
Study completion Jun 18, 2025
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-blind, Active-controlled, Non-inferiority, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HCP1004 as compared to RLD2401 in Chronic Low-Back Pain Patients
Conditions
- Chronic Low-back Pain
Interventions
HCP1004Drug
Test Drug
RLD2401Drug
Reference drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in VASTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hanyang University Seoul Hospital
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.